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Abstract: RNA-binding proteins (RBPs) are involved in regulating all aspects of RNA metabolism,
including processing, transport, translation, and degradation. Dysregulation of RNA metabolism
is linked to a plethora of diseases, such as cancer, neurodegenerative diseases, and neuromuscular
disorders. Recent years have seen a dramatic shift in the knowledge base, with RNA increasingly
being recognised as an attractive target for precision medicine therapies. In this article, we are going
to review current RNA-targeted therapies. Furthermore, we will scrutinise a range of drug discoveries
targeting protein-RNA interactions. In particular, we will focus on the interplay between Lin28 and
let-7, splicing regulatory proteins and survival motor neuron (SMN) pre-mRNA, as well as HuR,
Musashi, proteins and their RNA targets. We will highlight the mechanisms RBPs utilise to modulate
RNA metabolism and discuss current high-throughput screening strategies. This review provides
evidence that we are entering a new era of RNA-targeted medicine.
Keywords: RNA; microRNA; RNA-binding proteins; small molecules
1. Introduction
Eukaryotic post-transcriptional regulation is a critical process that controls RNA metabolism and
gene expression. RNA-binding proteins (RBPs) are key regulators of post-transcriptional events such
as RNA maturation, localisation, modification, silencing, translation, and turnover [1]. This is achieved
by recognising and binding specific RNA motifs or structures. So far, more than 1000 RBPs have been
identified in humans. Most of them are ubiquitously expressed, with only a small percentage showing
a tissue-specific expression pattern [2].
Mutations that affect post-transcriptional events often lead to serious diseases [3]. Hence, RNA-
targeted therapeutic strategies have shown promising results by correcting aberrant activities of
RNA metabolism and rescuing pathological phenotypes [4,5]. The most common approaches of
RNA-targeted therapies include RNA interference (RNAi) using small interfering RNAs (siRNAs),
microRNAs or ribozymes, modulating RNA-protein interactions, and RNA–RNA interactions using
chemically modified antisense oligonucleotides (ASOs) or small molecules. Besides these therapies,
mRNA delivery therapy is aimed at directly enhancing gene expression [6]. The first RNA-targeted
therapy, fomivirsen, was approved by the Food and Drug Administration (FDA) in 1998. Fomivirsen
is an ASO drug for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients.
The drug acts by targeting the mRNA of the CMV immediate-early-2 protein and inhibits viral
replication [7]. For the past twenty years, several RNA-targeted therapies have been marketed (Table 1).
Nowadays, with the development of next-generation chemistry and delivery techniques, more than 100
clinical trials are currently ongoing, covering a wide range of diseases, including cancer, neurological
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disorders, metabolic disorders, and infectious diseases (Table 2, Supplementary Table S1). ASOs and
siRNA therapies are the most popular strategies. These oligonucleotide-based drugs obtain improved
potency through chemical modifications and delivery vectors [8,9]. However, there are still some
challenges to overcome, such as off-target toxicity and immunogenicity, before they can be extensively
applied to routine clinical practice [10–12]. Alternatively, RNA-targeted small molecules have a few
advantages over the oligonucleotide therapies, in terms of their flexibility of drug delivery, manufacture
as well as administration [13].
In this review, we will explore the discovery process of FDA-approved and other pending
therapies for spinal muscular atrophy (SMA) that target survival motor neuron (SMN) pre-mRNA and
splicing regulatory proteins. We will also present two examples of potential RNA-targeted therapies,
which could work through regulating RBPs and RNA metabolism—Lin28 and let-7; as well as HuR
and Musashi proteins, and their RNA targets. We will review the drug discovery processes targeting
these RNA-protein interactions in depth, which utilised high-throughput screenings (HTS). The focus
will be placed on the screening strategies and the interplays between the RBP, its relevant drug, and the
RNA target. Finally, we will highlight several other discoveries towards RNA-targeted therapies of
human diseases. Together, this review provides insights into the pathways involved in uncovering
novel, RNA-targeted therapies.
Table 1. Marketed RNA-targeted therapies.
Drug Disease Target RNA TherapyType Company Ref.
Year
Approved
Exondys
51/Eteplirsen
Duchenne’s muscular
dystrophy (DMD)
Dystrophin
exon 51 ASO
Sarepta
Therapeutics [14] 2016 (FDA)
Givlaari™/
Givosiran
Acute hepatic
porphyria ALAS1 RNAi
Alnylam
Pharmaceuticals [15] 2019 (FDA)
Kynamro®/
Mipomersen
Hypercholesterolaemia ApoB-100 ASO
Ionis
Pharmaceuticals/
Kastle
Therapeutics
[16] 2013 (FDA)
Onpattro®/
Patisiran
Hereditary TTR
amyloidosis TTR RNAi
Alnylam
Pharmaceuticals [17] 2018 (FDA)
Ribavirin
RSV infection /Hepatitis
C/viral haemorrhagic
fevers
Viral RNA Smallmolecule Multi companies 2002 (FDA)
Spinraza®/
Nusinersen
Spinal muscular
atrophy (SMA) SMN2 ASO
Ionis
Pharmaceuticals/
Biogen
[18] 2016 (FDA)
Tegsedi®/
Inotersen
Hereditary TTR
amyloidosis TTR ASO
Ionis
Pharmaceuticals/
Akcea
Therapeutics
[19] 2018 (FDA)
Translarna®/
Ataluren
DMD Dystrophin Smallmolecule
PTC
Therapeutics [20] 2014 (EMA)
Vitravene/
Fomivirsen
CMV retinitis in HIV
patients
Major
intermediate
early region
2 of CMV
ASO
Ionis
Pharmaceuticals/
Novartis
[21] 1998 (FDA)
Vyondys
53/Golodirsen DMD
Dystrophin
exon 53 ASO
Sarepta
Therapeutics [22] 2019 (FDA)
Waylivra®/
Volanesorsen
Hypertriglyceridaemia/
Lipodystrophy ApoC-III ASO
Ionis
Pharmaceuticals/
Akcea
Therapeutics
[23] 2019 (EMA)
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Table 2. Representative RNA-targeted therapies in clinical trials.
Drug Disease Target RNAor RBP * Therapy Type Phase Trial #
ALN-AT-3/ Fitusiran Haemophilia A/B AT3 RNAi III
NCT03549871
NCT03754790
NCT03417102
NCT03417245
ALN-GO1/ Lumasiran Primary hyperoxaluriatype I HAO1 RNAi III
NCT04152200
NCT03905694
NCT03681184
ALN-PCSSC/ Inclisiran Hypercholesterolaemia PCSK9 RNAi III
NCT03814187
NCT03399370
NCT03397121
NCT03705234
Branaplam/ LMI070 SMA SMN2 Small molecule I/II NCT02268552
ISIS 2302/AP
1007/Alicaforsen
Pouchitis/ Crohn’s
Disease ICAM1 ASO III
NCT02525523
NCT00048113
LY900003/ ISIS 3521 Non-small cell lungcarcinoma PKC-a ASO III
NCT00017407
NCT00034268
MesomiR-1
malignant pleural
mesothelioma/
non-small cell lung
cancer
miR-16 miRNA mimic I NCT02369198
MRG-106/
Cobomarsen
Cutaneous T-cell
lymphoma/ Mycosis
fungoides
miR-155 ASO I/II
NCT02580552
NCT03713320
NCT03837457
MRG-201/ MiR-29/
Remlarsen Keloid miR-29b miRNA mimic II NCT03601052
OGX-011/ Custirsen Cancer Clusterin ASO III NCT01188187NCT01578655
RG-012/ SAR339375 Alport’s syndrome miR-21 ASO II NCT02855268
RG6042/ IONIS-HTT
RX/ ISIS 443139
Huntington’s disease HTT ASO III NCT03842969NCT03761849
RG7916/ RO7034067/
Risdiplam SMA SMN2 Small molecule II/III
NCT03779334
NCT02913482
NCT03032172
NCT02908685
RPI.4610/ Angiozyme Kidney cancer VEGFR-1 Ribozyme II NCT00021021
SPC3649/ Miravirsen Chronic Hepatitis C miR-122 ASO II
NCT02508090
NCT02452814
NCT01200420
Zotatifin /EFT226 Solid tumour EIF4A1 * Small molecule I/II NCT04092673
* If the target is an RBP. #—Number.
2. Targeting Lin28/let-7 Pathway
2.1. Let-7 Is Post-transcriptionally Regulated by Lin28
MicroRNAs (miRNAs, miRs) are a class of short non-coding RNAs that silence gene expression
post-transcriptionally. To date, more than 2000 miRNAs have been identified in Homo Sapiens [24].
In animals, miRNA transcript, the hairpin-like primary miRNA (pri-miR), is cleaved by the
microprocessor. The microprocessor complex is assembled by the RNase III Drosha, and DiGeorge
syndrome critical region 8 (DGCR8) proteins. The resultant stem-loop product is a precursor miRNA
(pre-miR), which is then transported to the cytoplasm, where it is further processed by the RNase
III Dicer [25]. Dicer cleavage removes the terminal loop of pre-miR and produces a miRNA duplex.
Only one strand becomes the mature miRNA, which complexes with Argonaute proteins as part of the
miRNA-induced silencing complex (mRISC) [26]. The mRISC triggers translation repression or mRNA
degradation through the base-pairing between the miRNA and the target mRNA [27].
Let-7 was first discovered as a regulator of stem cell differentiation in C. elegans. There are
nine mature let-7 miRNAs in the human let-7 family, encoded by 12 different genomic loci [28].
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The biogenesis of let-7 is blocked by Lin28 proteins through the interactions with the let-7 terminal
loop [29–32]. Let-7a-3 is an exception that evades Lin28A regulation [33]. Lin28 is abundantly expressed
in undifferentiated cells and its expression declines during differentiation, which is reciprocal to the
mature let-7 level [34]. Lin28A and Lin28B are the two paralogs in human cells, sharing a conserved
cold-shock domain (CSD) and two tandem Cys-Cys-His-Cys (CCHC) zinc finger domains. The CSD
domain and CCHC motifs bind the terminal loop of let-7 precursors at the GNGAY and GGAG motifs,
respectively [35] (Figure 1a). Lin28A recruits TUT4 (terminal uridylyltransferase 4) together with E3
ligase Trim25 to induce a 3’-uridylation of pre-let-7; therefore, preventing Dicer processing [36,37].
Alternatively, Lin28B retains pri-let-7 in the nucleoli, where the microprocessor is not available [38].
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Figure 1. Targeting the Lin28/let-7 pathway. (a) Interactions between Lin28 and pre-let-7. Cold-shock 
domain (CSD) and tandem CCHC motifs of Lin28 are shown in blue and green, respectively. Pre-let-
7 is shown in orange and mature let-7 in yellow. CSD and CCHC domains bind to the terminal loop 
of pre-let-7 at GNGAY and GGAG motifs, respectively. (b) Disruptors of Lin28/let-7 identified from 
HTS. CSD and CCHC motifs of Lin28 are shown in blue and green, respectively. Hit compounds 
identified through HTS as being disruptors of Lin28/let-7 are displayed. The targeting domains are 
notified. Disruptors with unclear mechanisms are pointed out. 
Let-7 inhibits the expression of many oncogenes, such as HMGA2, KRAS, and MYC, marking 
its function as a general tumour suppressor for carcinomas, exemplified by its role in lung cancer and 
multiple myeloma [28,39–41]. Interestingly, the let-7 family also targets the 3’-UTR of Lin28A and 
Lin28B, downregulating the expression of Lin28 proteins in embryonic neural stem cells [32]. This 
suggests a negative feedback mechanism of the Lin28/let-7 pathway. Lin28A/Lin28B overexpression 
is found in a plethora of advanced carcinomas, where the let-7 level is frequently repressed [42–44]. 
Figure 1. Targeting the Lin28/let-7 pathway. ( ) I t ractions between Lin28 and pre-let-7. Cold-shock
domain (CSD) and tandem CCHC motifs of Lin o n in blue and green, respectively. Pre-let-7
is shown in ora ge and mature let-7 in yellow. CSD and CCHC s bind to the terminal loop of
pre-let-7 at GNGAY and GGA motifs, respectively. (b) Disruptors of Lin28/let-7 identified fro HTS.
CSD and CCHC motifs of Lin28 are shown in blue and green, respectively. Hit compounds identified
through HTS as being disruptors of Lin28/let-7 are displayed. The targeting domains are notified.
Disruptors with unclear mechanisms are pointed out.
Let-7 inhibits the expression of many oncogenes, such as HMGA2, KRAS, and MYC, marking its
function as a general tumour suppressor for carcinomas, exemplified by its role in lung cancer and
multiple myeloma [28,39–41]. Interestingly, the let-7 family also targets the 3’-UTR of Lin28A and Lin28B,
downregulating the expression of Lin28 proteins in embryonic neural stem cells [32]. This suggests a
negative feedback mechanism of the Lin28/let-7 pathway. Lin28A/Lin28B overexpres ion is found in a
plethora of advanced carcinomas, where the let-7 level is frequently repressed [42–44]. Lin28 mediated
let-7 inhibition leads to the let-7 targets being reinstated. This contributes to accelerated tumorigenesis,
increased metastasis, as well as resistance to radiation and chemotherapies [45,46]. Based on this
evidence, the interruption of Lin28/let-7 is considered an attractive therapeutic approach [39]. Here we
will discuss the most recent drug screening techniques targeting this pathway, as well as the performance
of the hit compounds (Figure 1b).
2.2. FRET-Based HTS Targeting Lin28/let-7
Fluorescence resonance energy transfer (FRET)-based screenings are widely used in the study
of protein–protein interactions and have recently been applied in RNA-protein targeted screenings.
Normally, the two components are tagged with a donor or acceptor fluorophore, respectively. Quenching
of the donor fluorescence or enhancement of the acceptor fluorescence can be detected, allowing
interpretation of the interactions. The first small molecule disruptor of Lin28/let-7 was identified through
FRET screening of 16,000 drug-like small molecules from the Maybridge Hitfinder library [47]. Instead
of using two fluorophores, Lin28B was co-produced with EGFP (enhanced green fluorescent protein),
while pre-let-7-2a was conjugated with black-hole-quencher 1 (BHQ-1). The fluorophore-quencher
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design enhanced the assay’s sensitivity by improving the FRET effects without increasing the spectral
bleed-through. Fourteen hits were obtained after two rounds of HTS, among which the compound
1632 (N-Methyl-N-[3-(3-methyl[1,2,4]triazolo[4,3-b]pyridazin-6-yl)phenyl]acetamide) was verified
to upregulate the endogenous let-7 by two to three fold, in Huh7 cells. This was done using the
Renilla luciferase let-7 reporter assay and quantitative reverse transcription PCR (qRT-PCR) [47].
The compound 1632 also showed an obvious disruptive effect in the Lin28A/pre-let-7a-2 ELISA
with an IC50 of 8 µM. It acts by binding to Lin28 proteins but not RNA [47]. The binding domain
has not been clarified yet. Notably, this compound induced differentiation-like morphologies in
murine ESCs and inhibited tumorigenesis in human cancer cell lines, which are consistent with the
morphological changes triggered by upregulated let-7 [47]. An independent research group claimed
that 1632 treatment inhibited breast tumour growth and metastasis in mouse models. This was
achieved by blocking the Lin28B/MYC/miR-34a axis, which regulates tumour glucose metabolism and
the acidity of the microenvironment [48]. However, despite being a key regulator of this pathway,
let-7 level upregulation after 1632 treatment was not reported in this article. Thus, more evidence is
required to validate that the Lin28/let-7 pathway is the mechanism through which 1632 displays its
anti-cancer properties.
Another FRET-based screening assay labelled the terminal loop of pre-let-7a-1 at the 3’-end with
the quencher molecule BHQ-2 [49]. The fluorophore Cy3 was attached to the flexible linker between
the CSD and CCHC domains of Lin28A through unnatural amino acid mutagenesis. This labelling
strategy achieves closer proximity between the FRET donor and acceptor without hampering the
binding activity of the protein, thus enabling a higher quench efficiency (85%) and sensitivity (Z’ factor
= 0.94). A library containing a variety of 4,500 drug-like molecules was previously constructed using a
privileged substructure-based synthesis strategy [50]. A benzopyranylpyrazole-based hit compound
(denoted as compound 1) with micromolar IC50s was identified in the FRET screening followed by
validation with an electrophoretic mobility shift assay (EMSA) [49]. This hit compound blocks the CSD
of Lin28A, as shown in surface plasma resonance (SPR). Apart from working as an antagonist against
Lin28A/let-7a-1, the compound was also validated to play a similar role against Lin28B and let-7g in
EMSA. The antagonist decreased both Lin28A and Lin28B bound on pre-let-7a in RNA pulldown assays.
Moreover, it facilitated mature let-7g production in the Dicer processing assay. A twofold increase
was observed in the levels of 6 mature let-7 family members in JAR human choriocarcinoma cells.
Additionally, compound 1 showed no significant rescue of let-7 in Lin28 deficient or Lin28 knockdown
cells [49]. According to the luciferase reporter assays and western blot analysis, the oncogenic proteins
targeted by let-7 (HMGA2, c-Myc and Ras) were downregulated by the Lin28/let-7 disruptor in JAR
cells, emphasising its function in facilitating cellular let-7 biogenesis [49]. The Park group carried out
another HTS targeting Lin28/let-7 from an 8,400-compound library (Korea Chemical Bank) using the
same FRET-based platform [51]. The most potent hit, KCB3566, showed an IC50 of 11 µM, in EMSA.
By analysing KCB3566 analogues from the entire KCB libraries (430,000 compounds), KCB3602 was
selected as the best candidate by effectively disrupting Lin28A binding to the terminal loop of pre-let-7g
and pre-let-7-a-1 in EMSA (IC50 = 4.8 µM and 11 µM, respectively) [51]. SPR showed KCB3602 bound
to the CSD domain of Lin28A with a Kd of 5.9 µM. Compared with the hit from their first screening,
KCB3602 facilitated the biogenesis of let-7 and inhibited downstream oncogenic proteins at a lower
concentration (10 µM) [51]. Moreover, the novel disruptor displayed anti-cancer activities by relieving
paclitaxel-resistance and inhibited sphere-like growth in JAR cells [51].
2.3. FP-Based HTS Targeting Lin28/let-7
Another common screening strategy is fluorescence polarisation (FP). Excited by the corresponding
polarised light, a fluorophore linked to an unbound ligand depolarises the light emitted. While the
ligand is associated with a protein, the polarisation is retained due to a slower rotation of the bound
ligand. The affinity of ligand binding can be measured according to the difference of the polarised
light emitted by the fluorophore [52]. A previous FP-based HTS included 2,768 molecules, most of
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which came from two commercially available libraries. A small portion of molecules was designed to
specifically target nucleic acid structures [53]. In this screen, the terminal loop of pre-let-7g with natural
flanking nucleotides (5-nt each at both ends) was labelled with a 3’-fluorescein. The FP was acquired
in the presence of the N-terminal glutathione S-transferase (GST) tagged Lin28A. After two repeats
of the FP screening, 21 hits gave inhibition consistently greater than 50%. However, only four out of
21 hits showed equivalent inhibitive effects on full-length Lin28A/pre-let-7g in EMSA, and only two
compounds restored the mature let-7g level in the in vitro Dicer processing assay when the biogenesis
of pre-let-7g is partially inhibited by Lin28A [53]. The two hit compounds are 6-hydroxy-DL-DOPA,
a dopamine precursor and SB/ZW/0065, a benzo[a]phenoxazine. Whether these two hits could function
at a cellular level remains unvalidated. Furthermore, whether they are applicable for use in other let-7
family members is unknown.
A more recent FP-based screening was conducted using an extensive 101,017-compound pool,
combining six commercially available libraries [54]. The FP system was composed of the terminal loop
of pre-let-7f-1 with a 3’-FAM, and a truncated human Lin28A (with functional CSD and CCHC domains)
bearing a single mutation which enhances the let-7 binding affinity to the tandem CCHC pocket.
The modifications allowed a high sensitivity with a Z’ factor = 0.83. Twenty-seven hits were identified
with reproducible IC50s between 200 nM and 10 µM in the FP-based HTS. Six of the hits could inhibit
mouse Lin28A/TUT4 mediated pre-let-7g uridylation. Interestingly, the candidate compounds have
different working mechanisms. TPEN (N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine) is a
zinc chelator that interrupted the pre-let-7 binding at the CCHC zinc knuckle motifs. Another potent
inhibitor LI71 interacted with the CSD pocket of Lin28A and upregulated a range of mature let-7 levels
in embryonic and leukaemia cells, as detected by dual luciferase reporter assay and qRT-PCR. The let-7
levels detected in embryonic cells by qRT-PCR reached an impressive three to six-fold upregulation,
despite massive variations between the technical repeats [54].
2.4. Other HTS Targeting Lin28/let-7 and Conclusions
A novel fluorescence intensity-based binding assay (FL assay) was developed recently to screen
modulators of RNA-protein interaction, as protein-binding induced fluorescence enhancement
can be detected when nucleic acid fragments are conjugated with environment-sensitive organic
fluorophores [55]. Based on this FL assay, the interaction between Lin28A and 3’-TAMRA-labelled
terminal loops of pre-let-7-g was investigated using representative compounds from KCB, natural
products and drug-like small-molecule collections (Z’ prime = 0.56). The reliability of the method
was confirmed by three previously identified Lin28/let-7 disruptors, including the aforementioned
hit KCB3602 discovered by the same group [55]. The screening generated four initial hits, including
KCB170522, luteolin, rhynchophylline, and tenuifolin. However, only KCB170522 increased cellular
let-7 levels in JAR cells and inhibited the expression of let-7 targeted proteins (HMGA2, c-Myc and
Ras) [55]. Compared with FRET and FP, the FL assay-based screening is simple, with comparable
efficiency, at least in this case. Larger scale screening is required to prove the feasibility and effectiveness
of this novel screening approach.
Click chemistry is often applied in HTS by joining two biomolecules efficiently. The Garner group
developed a catalytic enzyme-linked click chemistry assay (cat-ELCCA) to monitor protein–protein
interaction and miRNA biogenesis in a high-throughput format [56–58]. Based on cat-ELCCA, an HTS
was carried out targeting Lin28/let-7 interaction by screening 127,007 small molecules from five libraries
(LOPAC, Prestwick, Maybridge, ChemDiv, and the University of Michigan Chemistry). Murine Lin28A
was immobilised and incubated with pre-let-7d carrying a 5′-trans-cyclooctene (TCO) click chemistry
handle. This was followed by click chemistry with methyltetrazine-conjugated horseradish peroxidase
(mTet-HRP). Lin28/let-7 interaction was detected by measuring chemiluminescence signals in the
presence of an HRP substrate [59]. The screening exhibited a Z’ prime of 0.5 and generated 1,468 initial
hits with more than 25% inhibition. Only two N,N′-(1,2-phenylene)-dibenzenesulfonamide derivatives,
namely CCG-233094 and CCG-234459, showed dose-dependent inhibition in both cat-ELCCA and
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EMSA with micromolar IC50s. The binding between Lin28A and these two compounds was confirmed
by SPR [59]. Nevertheless, whether the molecules can upregulate let-7 level and lead to any biological
consequences in the cellular context remains to be tested. This click chemistry-based HTS approach
provides fluorescence-free alternatives for screening protein-RNA regulators.
Lin28/let-7 is the best characterised RBP-miRNA interaction. These HTS are important examples
for drug discovery of RBP-miRNA modulators. Our group have identified Lin28A as a negative
regulator of the biogenesis of miR-9, through a distinct mechanism [60]. Additionally, hnRNP A1
negatively regulates let-7a levels [61–63]. We also found that miR-7 was modulated by cooperative
effects between two RBPs, which will be described in detail later [64]. This means that all identified
Lin28/let-7 compounds will have to be tested for their specificity and efficiency in cellular and animal
models before going forward in anti-cancer therapy trials.
3. Spinal Muscular Atrophy (SMA) RNA-Targeted Therapy
3.1. Pre-mRNA Splicing and SMA
Pre-mRNA splicing is a critical process in the production of functional mature mRNA in eukaryotic
cells. During the process, introns are removed, and exons are joined. Pre-mRNA splicing is catalysed
by a macromolecular ribonucleoprotein complex known as the spliceosome. The major spliceosome is
composed of five small nuclear RNAs (U1, U2, U4, U5, and U6), which combine with proteins to form
small nuclear ribonucleoproteins (snRNP). These snRNPs recognise conserved sequence elements
at 5’ splice sites (5’ss), 3’ss and branch points [65]. Alternative splicing occurs in 95% of human
genes, increasing protein diversity from the limited number of genes [66]. Trans-acting RBPs such as
serine-arginine-rich proteins (SR proteins) and heterogeneous nuclear ribonucleoproteins (hnRNPs)
modulate alternative splicing by interacting with cis-elements including the exonic splicing enhancer
(ESE), intronic splicing enhancer (ISE), exonic splicing silencer (ESS), and intronic splicing silencer (ISS).
In most cases, SR proteins work as activators, while hnRNPs act as suppressors. However, these RBPs
can play either role in a context-dependent manner [67]. Aberrant splicing is often implicated in
severe diseases such as cancer, Duchenne muscular dystrophy (DMD) and spinal muscular atrophy
(SMA). Therefore, correction of alternative splicing has the potential to be developed into various
new therapies [68,69]. Here we will review the development of SMA therapies targeting alternative
splicing, with a particular focus on the discovery of the first SMA drug (Figure 2).
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Figure 2. RNA-targeted therapy of SMA. The exons of SMN2 pre-mRNA are shown as squares
and introns as lines. Alternative splicing with exon 7 inclusion generates full-length SMN2 mRNA
and f nctional protein, w ile the loss of exon 7 re ults in non-functional protein. The j nction
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unknown mechanisms.
SMA is an autosomal recessive disorder characterised by motor neuron degeneration, leading
to progressive muscle weakness, atrophy and paralysis. SMA occurs in 1 in 10,000 new-borns and
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is dominated by SMA type I (Werdnig–Hoffmann disease), a fatal, infantile-onset subtype [70,71].
The majority of SMA is caused by the loss of survival motor neuron (SMN) proteins, as a result of
homozygous deletion or point mutation in the SMN1 gene. SMN2 also encodes SMN protein, but only
produces a small proportion of functional full-length proteins. Compared to SMN1, SMN2 bears a
single, silent C to T transition in exon 7, which induces exon 7 skipping during alternative splicing.
Therefore, the resultant truncated SMN protein is inactive and degraded rapidly [72]. The SMN2 copy
number is generally inversely correlated to clinical severity [73,74].
3.2. The Discovery of the First SMA Drug
Spinraza (nusinersen) is the first FDA approved drug for the treatment of SMA. The drug is a
2′-O-(2-methoxyethyl) (MOE) phosphorothioate-modified ASO. The modification endows the ASO
drug with an improved in vivo stability [75]. The discovery of Spinraza started with a two-step
ASO walk strategy by the Krainer group aiming to find modulators of SMN2 exon 7 alternative
splicing [76]. Nine ASOs were designed in a 5-nt step along the entire exon 7 in the initial coarse
screen. Two inhibitory regions of exon 7 inclusion were identified using in vitro (RNA-based) and
in vivo (cell-based) splicing assays. The following screen-tested 39 ASOs, ranging from 12-nt to
18-nt, complementary to the two putative targeting pre-mRNA regions. Two of the most potent
exon 7 inclusion stimulatory ASOs promoted the expression of corresponding reporter proteins in
HEK293 cells, as well as the full-length SMN protein in primary fibroblasts derived from a type I SMA
patient [76]. Following this, in collaboration with Ionis Pharmaceutics, the Krainer group performed a
second ASO screening, targeting intronic sequences flanking exon 7 [77]. Twenty 15-nt ASOs were
tested in the initial screen, with a 10-nt overlap between the neighbouring ASOs, covering 60-nt at the
end of intron 6 and the start of intron 7, respectively. The ASOs 11–25, targeting intron 7, showed the
strongest exon 7 inclusion effects in both in vitro and in vivo splicing assays [77]. The target region
was characterised as an intron 7 ISS, which showed a large overlap with a previously identified silencer
termed ISS-N1(10th–24th position in intron 7) [78]. Thirty-eight ASOs of different lengths targeting
the ISS were tested with the cell-based splicing assay. The most potent 18-mer and 15-mer were ASO
10–27 and ASO 9–23, respectively. The two ASOs were investigated in SMA type I patient fibroblasts.
They presented more efficient stimulatory effects in exon 7 inclusion and SMN protein production
when compared with the two best ASOs targeting exon 7 from the first screen [77]. After extensive
screening and optimisation, the MOE-modified ASO 10–27 was selected as the lead, as it showed the
greatest therapeutic potential [79]. The lead ASO was subsequently tested in different SMA mouse
models. It achieved promising therapeutic effects by correcting SMN2 splicing, rescuing necrosis,
and improving motor function and survival [77,79–81]. The optimised lead ASO was approved by the
FDA in 2016 and is now sold under the name of Spinraza. The drug is administrated to the human
central nervous system through intrathecal injection.
Spinraza has been shown to improve various clinically important outcomes, including increased
survival and enhancement of motor function. This is true for both early-onset type I disease and
later-onset type II and III diseases [82,83]. As the drug is still recently approved for clinical application,
the permanency of the effects of the drug is currently uncertain. However, it is hoped that as further
data becomes available, this picture will be increasingly clear. Furthermore, when accounting for
the considerable benefits already proven through the relatively short-term application of the therapy,
the potential for effective long-term therapy is promising. This is supported by the data provided by
the NUTURE study. Children in this study, treated with Spinraza while pre-symptomatic, showed
significant increases in life-expectancy and motor function when compared with what would be
expected for untreated children. Moreover, the study marks the potential benefit of initiating treatment
before the onset of symptoms [84].
It is clear that Spinraza functions by sequestering ISS-N1, but the mechanism of how ISS-N1
works as a negative SMN2 splicing regulator remains contentious. It was previously assumed that the
two putative hnRNP A1/A2 binding motifs in ISS-N1 were responsible for the inhibitory effects [77].
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However, recent evidence showed hnRNP A1 interacting with both binding sites through two RNA
recognition motifs (RRMs). Both interactions were essential to mediate the splicing repression [85].
Moreover, an increasing number of studies have suggested other motifs in ISS-N1, and secondary RNA
structures beyond the ISS-N1 region, are involved [75,86]. ASOs targeting other cis-acting elements,
as well as splice sites of neighbouring exons were explored [87,88]. A greater understanding of these
should facilitate complete comprehension of the mechanism involved in SMN2 splicing correction and
serve as potential therapeutic targets for different types of SMA.
Recently, a gene replacement therapy named Zolgensma (onasemnogene abeparvovec-xioi,
AVXS-101) was approved by the FDA for paediatric SMA patients with bi-allelic mutations in the
SMN1 gene [89]. Zolgensma delivers human SMN1 gene to motor neurons by adeno-associated virus
(AAV) intravenously, facilitating the production of functional SMN proteins. Despite there having been
no study directly comparing Zolgensma to Spinraza to date, several papers have provided indirect
comparisons. In general, these report a no difference in clinical efficacy, or a slight benefit leaning
towards the use of Zolgensma [90]. Similarly, in terms of cost-effectiveness, the two therapies would
appear to be similar, with Zolgensma again potentially being slightly cheaper long-term [91]. On the
whole, both therapies would appear to be economically beneficial when compared to no therapy, on top
of the substantial benefits to SMA patients [92].
3.3. Small Molecule SMA Drug Candidates Correcting SMN2 Splicing
Currently, two orally bioavailable small molecules targeting SMN2 splicing correction, risdiplam
and branaplam, are under evaluation in clinical trials. If approved, these drugs would advance SMA
treatment and improve patient accessibility beyond Spinraza and Zolgensma.
Risdiplam (RG7916) is structurally optimised from RG7800, the first small-molecule SMN2 splicing
modifier to enter human clinical trials [93]. Unfortunately, the trials were suspended due to ocular
toxicity in long-term animal studies [94,95]. The predecessor compound of RG7800 was identified
from a phenotypic HTS. The screening was based on an SMN2 minigene luciferase assay in HEK293H
cells using a proprietary library (PTC Therapeutics) containing more than 200,000 small molecules [96].
Only the full-length SMN2 minigene mRNA was in frame with the firefly luciferase sequence, so
exon 7 inclusion enhancers would generate increased luminescence. The positive hits were validated
using qRT-PCR and semi-quantitative end-point RT-PCR to confirm the increase of full-length SMN2
mRNA production. The identified small-molecule splicing modulators (SMN-C class compounds)
could increase full-length SMN2 protein levels in fibroblasts from different types of SMA patients.
This was highly selective towards SMN2 transcript, as assessed by RNA sequencing [96]. These small
molecules showed good oral bioavailability, as well as improved motor function and longevity in SMA
mouse models [96–98]. NMR structures indicated that SMN-C5 specifically stabilised a bulged adenine
at the exon-intron junction in the helix formed by U1 snRNA and exon 7 5’ss; therefore, promoting
U1 snRNP recognition and converting the weak 5’ss into a stronger one [99]. This introduces a new
concept for gene-specific alternative splicing correction termed as 5′ splice site bulge repair. Moreover,
SMN-C5 worked cooperatively with the splicing regulatory network, thus, displaying higher potency
in cellular models than in vitro assays [99]. Additionally, previous evidence indicated that SMN-C class
compounds bound to the ESE2 region on exon 7, through potential mechanisms relevant to SMN2
splicing activators, including hnRNP G, far upstream element-binding protein 1 (FUBP1), and KH-type
splicing regulatory protein (KHSRP) [100,101]. However, ESE2 binding is not the dominant cause of
splicing correction, and the action mode of these RBPs are not fully understood [99]. Compared to
RG7800, risdiplam showed enhanced potency and improved safety in preclinical studies [93]. The drug
candidate was well tolerated in a Phase 1 clinical study and is being investigated in Phase 2/3 studies
for all types of SMA [102]. Risdiplam is now under priority review for possible approval by the FDA.
Branaplam (LMI070) was discovered from a 1.4 million-compound library (Novartis) using a pair
of opposite SMN2 minigene luciferase reporters expressed in an NSC34 motor neuron cell line [103].
The screen resulted in less than 1.0% positive hits. These hits showed significant elevation of full-length
Int. J. Mol. Sci. 2020, 21, 2996 10 of 29
SMN2 reporter luciferase signal and a concomitant reduction of ∆exon 7 reporter signal. The average
Z’ factor and the robust Z’ factor were 0.59 and 0.71, respectively. The SMN2 splicing correction
activity of the hits was confirmed using qRT-PCR. Increases in SMN protein levels were evaluated in
SMN∆7 mouse myoblasts [103]. Based on a pyridazine core functional group identified from the hit
compounds, branaplam was developed through medicinal chemistry optimisation. This provided
advantages in potency, bioavailability, and safety [104]. This potential drug enhances full-length SMN
protein production and extends survival in a severe SMA mouse model [103]. Branaplam shares
a similar pharmacophore with the SMN-C compounds [100]. It also acts by stabilising the dsRNA
interaction between U1-snRNP and the 5’ss of SMN2 exon 7. This may occur in the major groove
proximal to the nGA motif at the exon portion of the predicted 5′ss junctions [103]. The precise action
site of branaplam at 5’ss is slightly different from SMN-C5 [100]. Branaplam is currently in a Phase 1/2
clinical trial for type I SMA treatment.
3.4. Other SMN2 Splicing Modifiers Identified by HTS and Conclusions
Secondary RNA structures are potential targets for small molecule splicing modifiers. Terminal
stem-loop 2 (TSL2) is a 19-nt RNA hairpin formed at the exon 7/intron 7 junction of SMN2, with its 3’ end
partially overlapping with 5’ss of exon 7 [105]. Prior to an HTS targeting TSL2, it was confirmed that
conformational changes in TSL2 could enhance SMN2 exon 7 inclusion [106]. From a 3,000-compound
in-house library, 304 small molecules were selected for the screening using in silico filtering, as the
molecules bear RNA recognition scaffolds, including indole, 2-phenyl indole, 2-phenyl benzimidazole,
and alkyl pyridinium [106]. The HTS was carried out using a fluorescence displacement (FD) assay,
with the help of a fluorescent indicator TO-PRO [106]. The fluorescence intensity of unbound TO-PRO
is negligible, but it will increase by 500-fold when TO-PRO binds to a structured RNA, which is the
TSL2 hairpin in this case. The replacement of the dye with an RNA ligand will result in a loss of
fluorescence [107]. The screening generated 54 initial hits with a Z’ factor of 0.7. The hit-induced
TSL2 conformational change was assessed by a 2AP assay, where TSL2 was labelled by a fluorescent
structural probe 2-aminopurine [106]. Nineteen candidates entered a secondary screen using a SMN2
minigene reporter assay in HeLa cells. Among these, homocarbonyltopsentin (PK4C9), a marine
natural molecule showed the strongest exon 7 inclusion effect with 25 µM EC50 [106]. PK4C9-induced
splicing correction was also effective in SMA fibroblasts and Drosophila motor neurons. Importantly,
the molecule raised functional SMN protein level and reversed SMN deficiency phenotypes in SMA
cells [106]. NMR and molecular modelling studies showed PK4C9 directly induced an opening
conformation of TSL2, leading to improved accessibility of 5’ss to splicing factors. Furthermore,
PK4C9 indirectly altered a pentaloop conformation of TSL2 into a triloop. The triloop conformation
is potentially favoured by exon 7 splicing [106]. With the realisation that secondary RNA structures,
critical for SMN splicing, are druggable, new avenues may open up for SMA therapy.
Luciferase SMN2 minigene reporters were extensively applied in the previous HTS of SMN2
splicing modulators [94,108]. Rigosertib, a well-known PLK (Polo-like kinase) inhibitor, was identified
as the best candidate from a drug screening using the SMN2 reporter cell lines [109]. Rigosertib
induced exon 7 inclusion and SMN protein restoration in motor neuron progenitors differentiated from
SMA patient-derived induced pluripotent stem cells (SMA iPSCs-pMN). SMA-related pathological
phenotypes were rescued by the candidate compound in this human SMA model cell line [109]. Another
very recent HTS described moxifloxacin as an exon 7 inclusion enhancer using a SMN2 minigene
reporter in Drosophila motor neurons. The effects were validated in patient-derived fibroblasts [110].
After the development and approval of Spinraza, the field of RNA-targeted drug development
for the therapy of SMA has expanded exponentially. The development of ASO drugs raised hope for
RNA-targeted therapies aimed at RBPs, previously considered undruggable. Additionally, the identified
splicing modifiers are useful tools to study the mechanism of how RBPs regulate alternative splicing.
A deeper understanding of the mechanism will, in turn, facilitate the development of more specific
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therapies. Finally, minigene reporters are good models for screening splicing modulators, if the hits
are validated using more physiologically relevant models.
4. Regulation of HuR and Musashi Proteins Binding to RNA
4.1. miR-7 Biogenesis is Controlled by HuR/MSI2 Complex
MicroRNA-7 (miR-7) is a brain-enriched miRNA. Dysregulation of miR-7 could contribute to
severe diseases, especially neurological disorders [111]. In glioblastoma (GBM) and Parkinson’s
disease (PD), the miR-7 level is often downregulated [112,113]. Restoration of miR-7 levels could have
therapeutic potential, as miR-7 targets the mRNA of epidermal growth factor receptor (EGFR) and
α-synuclein, which are overexpressed in brain tissue from GBM and PD patients, respectively [112–114].
Moreover, evidence has shown that PD is a risk factor in GBM [115,116].
Our group has identified that an RBP HuR (ELAVL1) binds to the terminal loop of pri-miR-7 and
recruits another RBP MSI2 (Musashi RNA-binding protein 2) to inhibit the biogenesis of functional
miR-7 [64]. We also showed that the pri-miR-7/HuR/MSI2 complex could be disrupted by oleic acid
(OA), a monounsaturated fatty acid (MUFA), resulting in elevated miR-7 levels [117]. Thus, disruptors
of pri-miR-7/HuR/MSI2 could become promising drug candidates for GBM and PD. However, there are
no relevant HTS reported so far, and the tagetome of miR-7 remain unknown. Here, we will review the
inhibitors of HuR and Musashi proteins binding to mRNAs, as well as the corresponding HTS strategies,
which might provide avenues for finding miR-7 enhancers by interrupting the pri-miR-7/HuR/MSI2
complex (Figure 3).
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4.2. HuR Binds AU-Rich Elements
HuR is expressed ubiquitously across human tissues. The protein often stabilises mRNAs bearing
AU-rich elements (AREs) in their 3’-UTRs. Most of the targeted ARE-RNAs encode oncogenic proteins,
highlighting a crucial role of HuR in regulating the development and progression of multiple human
cancers [118]. HuR inhibition can sensitise tumour cells to cancer therapies [119,120]. Interestingly,
HuR represses SMN2 splicing by binding to the -44 region in intron 6, implying its potential to
become an SMA target [121]. HuR contains three RRMs. The N-terminal tandem RRMs (RRM1 and
RRM2) are responsible for ARE binding, and the C-terminal RRM (RRM3) can bind ARE and poly-A,
with suggested roles in protein–protein interaction, dimerisation, post-transcriptional modifications,
and stabilisation [122,123]. However, the roles of RRM3 in the context of full-length HuR remain
controversial [122–124].
4.3. HTS Targeting Different RRMs of HuR
A confocal fluctuation spectroscopic screening assay was performed with recombinant
HuR12 (containing only RRM1 and RRM2), and tetramethylrhodamine (TMR) labelled ARE-RNA
(unspecified) using a 50,000-compound library composed of microbial, mycological, and plant extracts
(Novartis) [125]. In complex with HuR, the fluorescently labelled ARE-RNA should have a slower
rotation, resulting in an increased fluorescence anisotropy measured by 2D-FIDA (two-dimensional
fluorescence intensity distribution analysis). The Z’ prime of this HTS was 0.86. Fifty primary hits were
identified with more than 40% inhibition of HuR-induced anisotropy increase. The active fractions
were isolated using reverse-phase HPLC, and five compounds were selected from the fractions as
they showed the strongest HuR-RNA inhibition according to NMR, IR, and MS [125]. Three out
of the five molecules inhibited full-length HuR from binding to the AREs of interleukin-2 (IL-2),
tumour necrosis factor-α (TNF-α), cyclooxygenase 2 (Cox-2), and IL-1β in a concentration-dependent
manner, as monitored by 2D-FIDA [125]. The three nanomolar inhibitors were dehydromutactin,
MS-444, and okicenone. They interfered with HuR homodimerisation and cytoplasmic trafficking;
prevented HuR-mediated ARE-mRNA stabilisation in the cytoplasm, and decreased ARE cytokine
expression in primary human monocytes [125]. MS-444 is the most potent compound, and it has
been proven to effectively disrupt HuR targeting to different mRNAs by several independent research
groups [120,126–128]. Notably, the anti-cancer effects of MS-444 through HuR inhibition were observed
in malignant pancreatic [120,129], colorectal [130,131], melanoma [132], and glioma cells [133] in vitro
or in xenograft mouse models. The drug development of MS-444 by Novartis has not been reported
yet, so the future of this HuR inhibitor is uncertain.
Confocal nanoscanning (CONA) screening from one-bead-one-compound libraries was used to
look for HuR ligands, specifically targeting RRM3 and elucidate the controversial functions of the
orphan RRM3 pocket [122]. Eighty-nine thousand heterocyclic compounds were immobilised on 90
µm TentaGel beads. Each compound class comprised four different building blocks, representing
a total of 2.2 million compounds. HuR binding hits were detected as fluorescent rings when Cy5
tagged HuR was captured by compounds on the beads. The ring intensities were proportional to the
amount of bound HuR. HuR RRM3 selective hits (binding full-length HuR but not HuR12) with the
highest intensities were found in sub-libraries of pyrrole and dicarboxylic acid scaffolds [122]. Forty-six
molecules were identified from the isolated hit beads by MS decoding, four of which were found
repetitively. The four hit compounds were resynthesised, and their selective binding to HuR RRM3 was
confirmed in CONA. Compound H1N belongs to the dicarboxylic acid scaffold sub-library and showed
the highest binding affinity in the CONA screen, as well as competition assays [122]. With the help of
H1N bead resin in CONA, an ATP-binding pocket associated with 3′-terminal adenosyl transferase
activity was identified in HuR RRM3 [122]. Notably, the ATP-binding affinity is not detected in
other conventional binding assays using isolated RRM3 [123]. The on-bead screen strategy allows the
identification of low affinity but specific ligands. CONA is also very helpful with the characterisation
of binding domains, especially in this case, as both full-length and RRM3 HuR have poor solubilities.
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4.4. Other HuR/ARE-RNA Disruptors and Therapeutic Effects
A small-scale screen targeting HuR and TNF-α ARE-RNA was completed using EMSA.
One hundred seventy-nine compounds, obtained from the Korea Research Institute of Chemical
Technology, were tested [134]. Three compounds, quercetin, b-40, and b-41, showed strong disruptive
effects with IC50s of 1.4, 0.38, and 6.21 µM, respectively. Quercetin and b-40 could destabilise TNF-α
mRNA and decrease levels of secreted TNF-α [134]. Independent research indicated that quercetin
displayed significant HuR-mediated IL-6 suppression in vitro and in vivo [135]. EMSA is widely
applied to validate protein–RNA interactions. However, due to the technical limitations, EMSA is not
efficient for robust, high-throughput screenings.
An AlphaScreen (PerkinElmer)-based HTS was developed to identify inhibitors of HuR binding
to TNF-αmRNA [136]. The interaction between biotinylated TNF-α ARE, and c-Myc-tagged HuR was
monitored using Streptavidin-Donor beads and anti-c-Myc-Acceptor beads. The Z’ prime was 0.84,
and a pilot screen was performed with a 2,000-molecule library (Spectrum Collection, MicroSource
Discovery, USA). The library contained clinically approved drugs, natural products and other bioactive
components. Ten per cent of hits were rescreened and two compounds, cethylpiridinium chloride
and mitoxantrone, were shown to prevent the formation of HuR/TNFα ARE complex by EMSA [136].
HuR binds to ARE-RNA of sex-determining region y-box2 (SOX2) and induces RNA degradation.
Mitoxantrone disrupted the interaction between HuR and SOX2 mRNA, resulting in an upregulated
level of SOX2 mRNA and protein in mesenchymal stem cells [137]. The same AlphaScreen assay was
applied to a small-scale screen from 107 commercially available anti-inflammatory compounds [138].
The most potent inhibitor was DHTS (15,16-dihydrotanshinone-I), which prevented the associations
between HuR and TNFα mRNA with nanomolar IC50s. Furthermore, DHTS downregulated both
mRNA and protein levels of TNFα and exhibited anti-tumour effects in human breast cancer cells [138].
Structural analysis has shown that DHTS competes with RNA by interfering with both RRM1 and
RRM2 of HuR, but the inhibitor is limited to mRNAs with low HuR affinity [139]. The compound
inhibited colon cancer cell growth in vitro and in a xenograft mouse model in a HuR-dependent
manner [139]. DHTS showed effects similar to MS-444 in glioma, by inhibiting HuR multimerisation
and decreasing cellular HuR protein level. Importantly, DHTS showed dose-dependent cytotoxicity
towards glioma cells [140]. Based on the structure of DHTS, a series of tanshinone mimics were
synthesised. Among these, tanshinone mimic 6a and 6n were more potent HuR/ARE-RNA disruptors
when compared to DHTS [141]. 6a and DHTS bind at the same region of HuR, illustrating potential
structure-activity relationships (SARs) for HuR inhibitors [141]. The tanshinone mimics affected cell
viability in breast and pancreatic cancer cells. However, each of these mimics was less efficient when
compared to DHTS [141].
An FP-based HTS has been reported to screen a library of around 6,000 compounds (an
in-house library and a library of FDA approved drugs) for HuR/MSI1 ARE-RNA disruptors [142].
The screen generated an initial hit rate of 0.7% with a Z’ factor of 0.79. Six hits (CMLD 1-6) shared a
coumarin-derived core and the HuR/ARE disruptive effects were validated using AlphaLISA (Amplified
Luminescent Proximity Homogeneous Assay), SPR, the ribonucleoprotein immunoprecipitation (RNP
IP) assay, and the luciferase reporter assay [142]. CMLD-2 was the most potent candidate compound
among the six hits, with a Ki of 0.35 ± 0.3 µM [142]. Most of the hits displayed moderate cytotoxicity in
colon cancer and pancreatic cancer cells. In colon cancer cells, CMLD-1 and CMLD-2 disrupted HuR
binding to MSI1 and XIAP mRNAs, and therefore, blocking the Wnt signalling pathway. The anticancer
properties were related to apoptosis and autophagy triggered by destabilisation of HuR targets Bcl-2
and XIAP [142]. However, the evidence is not sufficient to prove the SAR of coumarin derivatives as
HuR/ARE disruptors and the binding interface has not been confirmed. In particular, CMLD-2 showed
therapeutic potentials in lung, breast, and thyroid cancer cells in vitro, with implicated mechanisms
relevant to HuR-RNA disruption [143–145].
The above FP assay was applied to screen about 2,000 compounds from the National Cancer
Institute library (NCI Diversity Set II, Natural Products Set, and Approved Oncology Drugs Set) and
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an in-house library [146]. The hit compounds were azaphilones, a class of compounds derived from a
fungal natural product, asperbenzaldehyde. The most potent candidate was AZA-9 (IC50 = 1.1 µM),
which was also effective in disrupting HuR/c-Fos ARE (IC50 = 1.2 µM). Through structural studies,
AZA-9 was assumed to competitively bind HuR RRM1 and RRM2 in the RNA binding cleft [146].
Another FP-based HTS was carried out from the NCI library (diversity set V, 1597 compounds) to
identify small HuR inhibitors [147]. The screening focused on the interaction between 5’-Fam-labelled
c-Fos ARE-RNA and full-length HuR, generating a Z’ factor of 0.8. The primary hits were tested
in an NMR-based assay with saturation transfer difference detection (STD-NMR), which provided
information on the direct interaction between HuR and the compounds [147].
Using differential scanning fluorimetry (DSF), suramin was recognised as an HuR ligand from an
FDA-approved drug library (Pharmakon, 1600 drugs) [148]. Although suramin regulated ARE-mRNAs
and the corresponding protein levels in tongue carcinoma cell lines, there is no evidence revealing that
the drug functions as a direct HuR/ARE disruptor [148].
4.5. Musashi Proteins Recognise Specific RNA Motifs
Human Musashi proteins have two paralogues MSI1 and MSI2, sharing approximately 80% amino
acid similarity. Both proteins have two highly conserved N-terminal RRMs, with MSI1 mainly binding
(G/A)U1–3AGU sequences, whereas MSI2 prefers ACCUUUUUAGAA and UAG motifs [149–151].
The C-terminal region of Musashi proteins harbours protein interaction sites, which regulate the
translation of Musashi targets [152]. Musashi proteins normally express in stem and progenitor
cells and regulate cell differentiation and organ development [153]. Aberrant high expression of
Musashi proteins is associated with aggressive tumours, consistent with their roles as translational
modulators of some well-recognised oncogenic signalling pathways, including Numb/Notch and
PTEN/mTOR [153]. Overexpressed Musashi proteins are found in gliomas, colorectal adenocarcinomas,
pancreatic adenocarcinomas, breast cancer, lung cancer, and hematopoietic malignancies [150,153–155].
Interestingly, the 3’-UTR of MSI1, but not MSI2, bears ARE targeted by HuR, and MSI1 expression is
positively regulated by HuR in GBM [156].
4.6. HTS Targeting MSI/RNA Interactions
A 1536-well format FP-based HTS has been developed to identify inhibitors of MSI RNA binding
activities [157]. The screen library combines 6,208 compounds from several commercial sources
including MicroSource, Prestwick and Tocris. These contain known drugs, experimental bio-actives
and natural products [157]. An 8nt-RNA oligo (GUAGUAGU) was selected in this screen, as it was
determined to be the shortest oligo with high MSI binding affinity and specificity according to an
SYBR-based EMSA assay. The screening was performed using Cy3 labelled RNA oligo and GST fused
MSI1 (Z’ = 0.58) or MSI2 (Z’ = 0.61) in a 1536-well plate. Seventeen hits were identified from the initial
screen with more than 50% inhibition, five of which inhibited both MSI1 and MSI2. The hits were tested
in a secondary screen using a dose-dependent FP assay in a 384-well format. Three inhibitors showed
less than 10 µM IC50s towards both Musashi proteins, with slightly higher affinity to MSI1 [157].
The three hits were further validated in an SYBR-based EMSA assay. Following this, one of the hits, Ro
08-2750 (Ro), showed an IC50 of 2.7 ± 0.4 µM to MSI2 in an FP assay. Ro bound directly to MSI2 (Kd =
12.3 ± 0.5 µM) in a MicroScale Thermophoresis (MST) assay [158]. The selectivity of Ro was tested
against RBPs sharing conserved RRMs or similar mRNA targets with MSI2, by MST. The molecule
showed weak binding (Kd ≈ 200 uM) towards SRSF2 and SYNCRIP, with nearly no binding to HuR.
Strong structural and biochemical evidence suggests that Ro interacts with key residues at RRM1 of
MSI2 [158]. Importantly, Ro significantly reduces the binding of MSI2-targeted mRNAs, including
TGFBR1, c-MYC, SMAD3, and CDKN1A, in an RNA-IP assay. It also inhibits the regulatory effects
of MSI2 on the relevant proteins (TGFβR1, c-MYC, SMAD3, HOXA9, and P21) in human leukaemia
cell lines [158]. Furthermore, Ro inhibits leukemogenesis in a murine myeloid leukaemia model
in vivo, with a concomitant decrease of intracellular c-MYC levels [158]. The efficacy of Ro as an MSI2
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inhibitor firmly supports the reliability of this HTS platform, where an artificial RNA oligo, designed by
combining MSI binding motifs, is applied as the RNA probe. The optimised RNA probe allows higher
selectivity to MSI binding when compared with other natural target mRNAs. This approach may also
benefit the screen outcomes because the hits could have greater potential to interrupt universal mRNA
targets of a selected RBP when it is desired to achieve a maximum therapeutic effect.
Another FP-based HTS uses a previously identified RNA probe (AGCGUUAGUUAUUUAG
UUCG) containing two MSI1 consensus recognition motifs [149]. The interactions between the
fluorescein labelled RNA probe and His-tagged recombinant MSI1 dual RRMs (amino acids 7–192)
were monitored using FP, during the treatment of two libraries—LOPAC (1280 compounds) and the
Chembridge library (30,000 compounds) [159]. The Z’ prime was 0.7 ± 0.2, and four inhibitors were
identified from the screen, including OA, an 18-carbonω-9 MUFA with a Ki of 1.2± 0.4µM. FP and EMSA
assays indicated that the RNA binding activity of both MSI1 and MSI2 could be specifically inhibited by
ω-9 cis unsaturated fatty acids between 18 and 22 carbons [159]. Computational docking and molecular
dynamic simulations elucidated an allosteric inhibition mechanism, where OA induced a conformational
change on MSI1 RRM1 and disrupted RNA recognition by key residues [159]. OA exclusively inhibited
oligodendrocyte progenitor cell proliferation in the presence of MSI1. Stearoyl-CoA desaturase
(SCD), an enzyme which catalyses MUFA synthesis is regulated by MSI1, suggesting a feedback
loop of MUFA inhibiting MSI1 [159]. Based on this paper, our group proved that OA facilitated the
biogenesis of pri-miR-7 in vitro and in HeLa cells, by remodelling the pri-miR-7/HuR/MSI2 complex.
However, this only occurred at relatively high concentrations (500 µM to 1 mM) [117]. Considering
OA showed poor bioavailability and high cellular toxicity at the effective concentrations, it is still
necessary to seek alternative molecules disrupting the pri-miR-7/HuR/MSI2 complex. On the other
hand, pre-treatment of OA exacerbated kidney fibrosis in unilateral ureteral obstruction (UUO) mouse
models. This was related to increased P21 expression and enhanced Numb/Notch signalling as a result
of MSI1 inhibition [160]. It implies that the MSI1-mediated pathways act as a double-edged sword in
different human pathogenesis.
4.7. Other Molecules Identified from HTS Targeting MSI/RNA and Conclusions
(−)-gossypol is a natural product extracted from cottonseed. The molecule targets anti-apoptotic
activities of Bcl-2 family proteins and has been studied in clinical trials for the treatment of a variety of
cancers [153]. (−)-gossypol was identified as an MSI inhibitor in an FP-HTS carried out using GST
tagged full-length MSI1, and fluorescein-labelled RNA probe (UAGGUAGUAGUUUUA), a known
MSI1 binding motif located at the 3’-UTR of Numb mRNA [161]. The screen included about 2000
compounds from NCI (Diversity Set II) and an in-house library. (−)-gossypol showed 86.7% inhibition
in the FP screen and a Ki of 476 ± 273 nM. The MSI inhibitor interacted with RRM1, as shown by
SPR and NMR data [161]. Further in vitro and in vivo studies showed that (−)-gossypol could repress
colon cancer growth through the control of downstream targets of MSI1 [161]. The discovery of the
new target and pathway of (−)-gossypol provides an alternative route for its development as an
anti-cancer drug. In a more recent FP-based screening, gossyopolone (Gn) was identified with a Ki
of 12 ± 2 nM against full-length MSI1, and 7.0± 0.3 nM against full-length MSI2 [162]. Gn is a major
metabolite of gossypol, and it showed higher affinity than (−)-gossypol in the same experimental
conditions [162]. Gn disrupted the interaction between the Numb RNA probe and MSI1/MSI2 in the
FP assay, displaying its role as a dual inhibitor [162]. The MSI inhibitor also directly interacted with
the RRM1 of MSI1. Gn induced apoptosis and autophagy in colon cancer cells, with concomitant
repression of Notch/Wnt signalling [162]. A Gn-loaded liposome (Gn-lip) was delivered to colon
cancer xenograft mouse models through a tail vein injection. The treatment of Gn-lip inhibited tumour
growth and downregulated Notch/Wnt downstream proteins in tumours [162]. The use of PEGylated
liposomes improved the biocompatibility and drug efficacy of Gn in vivo, providing a strategy for
drug delivery of MSI inhibitors with poor bioavailability.
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An MSI1 inhibitor, luteolin, was discovered from an FP screening using a total of 25,588
compounds from several libraries, including Prestwick, LOPAC, Cambridge NovaCORE, and the Life
Chemical FSP3-enriched libraries [163]. The assay utilised MSI1-RRM1, and 5’-Cy3 labelled RNA
probe (GUAGUAGU) with a Z’ factor of 0.72. Luteolin directly binds to MSI1-RRM1 with a Kd of
3 µM, as determined by SPR. In GBM cells, the compound inhibited the expression levels of MSI1
targets including PDGFRα, IGF-IR, EGFR, CCND1, and CDK6. Importantly, it could suppress the
MSI1-induced luminescence from the PDGFRα 3’-UTR luciferase reporter [163]. Moreover, luteolin
inhibited proliferative and metastatic properties in GBM cells and organoids [163]. Surprisingly,
the aforementioned HuR/TNF-α mRNA inhibitor quercetin is a close analogue of luteolin [134].
Quercetin also interacted with MSI1-RRM1 in the FP competition assay and presented similar but
less potent anti-proliferation effects in GBM as luteolin [163]. This implies quercetin may act as a
dual inhibitor targeting both HuR and MSI1 and interrupting their RNA-binding abilities. It would
be interesting to see if quercetin also targets MSI2. If this were the case, it will become a promising
candidate to rescue the HuR/MSI2-mediated inhibition on miR-7 biogenesis. Moreover, both quercetin
and luteolin dissociated Lin28A/let-7g in vitro with IC50s less than 2.5 µM [55]. Despite the fact that
these two flavone analogues appear to be less selective, they are interesting ligands targeting different
RNA-binding domains and would be useful for the investigation of various RBP/RNA interactions.
So far, structural knowledge of HuR and Musashi proteins is very limited. The structures of HuR
RRM1-2 and RRM3 were solved separately [123,124,164]. Similarly, MSI1 has two separate RRMs
structures [165,166]. MIS2 only has RRM1 structures published [158,167]. Most of the HuR/ARE
disruptors target the RRM1-2, while the sole RRM3 ligand has shown weak interference with full-length
HuR/ARE complex [122]. How RRM3 coordinates with the N-terminal RRMs is yet to be completely
understood. For Musashi proteins, all the above inhibitors interact with RRM1. The binding modes
of the molecules with full-length Musashi proteins are unknown. Based on a model structure of
RNA-bound MSI1 RRM 1–2, it has been deduced that the tandem RRMs will adopt certain orientations
upon RNA binding [166]. Thereby, more information is needed to address the working mechanism of
these drug candidates, in the context of full-length RBPs. Moreover, the interaction between pri-miR-7,
HuR, and MSI2 has not been studied yet. Currently, our group is developing a novel screening
approach targeting this pathway. Utilising the CONA platform, the screening will be performed in cell
lysates, which may generate more bio-functionally relevant hits.
5. Other Discoveries Towards RNA-Targeted Therapies
Aside from the above three stories, there are more potential RNA-targeted therapies being
developed. The following section will briefly outline some notable examples.
Myotonic dystrophy type 1 (DM1) is caused by the expansion of a (CTG)n repeat sequence in the
dystrophia myotonica protein kinase (DMPK) gene 3’UTR [168]. From an in vitro HTS using ASOs
complementary to DMPK mRNA, the ASO ISIS 486178 was described as the best candidate, exhibiting
high potency in DMPK RNA reduction, as well as good tolerability in animals [169]. The lead ASO
could ameliorate muscle weakness symptoms in DM1 mouse models, without exerting observed
toxicity [170]. This provides evidence suggesting that a reduction of the levels of CUG RNA may
improve the muscular function of DM1 patients [170].
A different expansion of G4C2 repeats in the c9orf72 gene is the most causative factor of amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia (FTD). The transcribed G4C2 repeats are responsible
for the accumulation of toxic RNA foci, sequestration of proteins, as well as the production of dipeptide
repeat proteins (DPRs), which are a result of non-ATG (RAN) translation [171]. From a FRET-based
screen, small molecules targeting the G4C2 repeat RNA G-quadruplexes were identified. These RNA
binders could reduce the G4C2 foci and DPRs in c9orf72 patient-derived neurons [172]. Another
small molecule specifically binding the hairpin form of G4C2 repeat RNA was discovered from a
fluorescence displacement assay. According to in vitro and cell-based assays, this molecule inhibits
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RAN translation and hnRNP-H sequestration of the target, blocking these two potential mechanisms
driving the c9ALS/FTD pathogenesis [173].
In another study, a small molecule microarray (SMM) containing 20,000 drug-like molecules
was previously amassed. SMM screening was performed against a fluorescently labelled RNA
element, the HIV-1 transactivation response (TAR). This resulted in the discovery of TAR hairpin
stabilisers, which provide anti-HIV activity in T-lymphocytes [174]. Further work was performed to
uncover the noncanonical binding mode between TAR and the synthesised derivatives of the initial hit
compound [175].
The discovery of small-molecule miRNA regulators has been previously reviewed, summarising
three major strategies, including HTS from large libraries, focused screening using known RNA binders,
such as aminoglycosides, as well as drug design targeting RNA secondary structures or relevant
RBPs [176]. The use of focused screening leads to a higher success rate than HTS; however, the resultant
RNA ligands are likely to lack selectivity. As for the drug design, it is necessary for it to be based on
previously validated, functional miRNA modulators [176].
Streptomycin is a well-known aminoglycoside antibiotic. It was previously identified as a miR-21
inhibitor, from a focused screen using a cell-based luciferase reporter assay [177]. Streptomycin binds
to pre-miR-21, and thus blocks Dicer cleavage. Reduced miR-21 levels allow the rescue of its targets,
such as PDCD4. This could translate into the potential for cancer therapy, with the restored PDCD4
function observed after streptomycin treatment in vitro and in cells [177].
Finally, Disney et al. developed a novel focused screen platform named dubbed two-dimensional
combinatorial screening (2DCS). This is a library-vs-library screen where a small molecule microarray is
hybridised with an RNA element library, allowing the definition of interactions between the compounds
and steric RNA structures [178,179]. Using a 2DCS against two aminoglycosides derivatives, the internal
loop of pri-miR-10 was found to bind G Neo B, which prevents Drosha processing during miR-10
biogenesis [180]. More recently, the Disney group identified a functional inhibitor of the oncogenic
miR-18a, based on 2DCS combined with statistical analysis approaches [181].
These RNA binders have shown great potential as future therapeutics, targeting viral RNA,
oncogenic miRNA, as well as abnormal mRNA repeats. To find out whether and how the relevant
RBPs become involved in the field will be a topic of great interest.
6. Conclusions and Future Perspectives
Throughout this review, we have summarised commercialised RNA-targeted therapies and
those under evaluation in clinical and preclinical studies. These drugs are based on different
formats including ASOs, siRNAs, miRNA mimics and small molecules. The therapeutic effects are
achieved through the regulation of RNA maturation, splicing, interference, translation and stabilisation.
More possibilities of drug formats and therapeutic mechanisms have been discussed, including
peptides [182], aptamers [183] and RNA editing with CRISPR-Cas13 [184]. Over the past five years,
an increasing number of RNA-targeted drugs have been approved. There is no doubt that more will be
utilised to enable the treatment of previously “incurable” diseases in the near future. Spinraza, the first
effective SMA drug, is an excellent example.
By reviewing a number of HTS targeting RBPs and their regulatory RNAs, we have reached
several important conclusions, which may benefit strategy making for future RNA-targeted drug
discovery in the preclinical stage. First of all, we have shown a collection of different screening
assays. FRET and FP are the most common assays applied in the identification of disruptors between
two-component RBP-RNA interactions. Luciferase minigene reporter assays have been frequently
used to identify splicing modifies. This is a paradigm of phenotypic screens. Alternatively, some novel
screening strategies are being developed, such as CONA and FD assay [107,122]. More RNA-targeted
HTS approaches have been reported, such as in silico virtual screens, and small molecule microarray
screening [185,186]. Secondly, the understanding of RNA motifs and RBP domains in the interaction
interface is crucial. This is true for the selection of RNA probes, tagging of the protein domains, as well
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as for enabling the study of the mechanism of candidate drugs. Sometimes, the discovery of ligands
can, in turn, elucidate the action mechanism of RBP-RNA interplays. For example, an ATP-binding
pocket was identified by studying the inhibitors of HuR-RRM3 [122]. Cis-elements controlling SMN2
pre-mRNA splicing were confirmed through ASO screenings [77,106]. Finally, positive hits obtained
from screening assays need to be validated in more physiologically relevant models. Ideally, hits should
be tested against full-length RBPs, as well as being investigated in the cellular context to determine
whether they can still regulate the metabolism of the target RNAs.
Several aforementioned hit compounds have shown promising therapeutic effects in the preclinical
and clinical tests. Risdiplam is the most advanced investigational medicine, awaiting the FDA’s decision
under priority review. It is being studied in all types of SMA patients aged from 0-60 years old.
If approved, risdiplam will become the first self-administrated SMA medicine. Some of the Lin28/let-7
disruptors (1632 and KCB3602), as well as HuR (MS-444, DHTS and CMLD-2) or MSI inhibitors (Ro,
luteolin, (−)-gossypol and Gn), have exhibited anti-cancer properties in vitro or in vivo. However,
further research needs to be undertaken to evaluate their efficacy, bioavailability and safety before
entering the clinical studies. Beyond these three examples, therapies targeting viral RNAs [187,188],
RNA cleavage through RNase recruitment [189,190], mRNA translation by inhibiting eukaryotic
translation initiation factors [191], as well as premature translational termination caused by nonsense
mutations [192], are being developed. With respect to the huge number of RNA-targeted therapies
in preclinical studies and clinical trials, it is apparent that these therapies will form a key part of
personalised, precision medicine in the future.
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Abbreviations
2AP 2-aminopurine
2D-FIDA two-dimensional fluorescence intensity distribution analysis
ALAS1 5’-aminolevulinate synthase 1
ApoA/B/C apolipoprotein A/B/C
ARE AU-rich element
ASO antisense oligonucleotide
AT3 antithrombin III
ATP adenosine triphosphate
Bcl-2 B-cell lymphoma 2
BHQ black-hole-quencher
C.elegans Caenorhabditis elegans
cat-ELCCA catalytic enzyme-linked click chemistry assay
CMV cytomegalovirus
CONA confocal nanoscanning
CRISPR-Cas clustered regularly interspaced short palindromic repeats-associated protein
CSD cold-shock domain
DGCR8 DiGeorge syndrome critical region 8
DHTS 15,16-dihydrotanshinone-I
DMD Duchenne’s muscular dystrophy
EC50 The half-maximal effective concentration
EGFR epidermal growth factor receptor
EIF4A eukaryotic translation initiation factor 4A
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ELISA enzyme-linked immunosorbent assay
EMSA electrophoretic mobility shift assay
ESC embryonic stem cells
ESE exonic splicing enhancer
ESS exonic splicing silencer
FD assay fluorescence displacement assay
FDA Food and Drug Administration
FL assay fluorescence intensity-based binding assay
FP fluorescence polarisation
FRET fluorescence resonance energy transfer
GBM glioblastoma
Gn gossyopolone
GST glutathione S-transferase
HAO1 hydroxyacid oxidase 1
HIV human immunodeficiency virus
HMGA2 high mobility group AT-hook 2
hnRNP heterogeneous nuclear ribonucleoprotein
HPLC high-performance liquid chromatography
HTS high-throughput screening(s)
HTT huntingtin
HuR human antigen R
IC50 the half-maximal inhibitory concentration
ICAM1 intercellular adhesion molecule 1
IL interleukin-2
IP immunoprecipitation
IR infrared spectroscopy
ISE intronic splicing enhancer
ISS intronic splicing silencer
Kd dissociation constant
Ki inhibition constant
KRAS Kirsten rat sarcoma 2 viral oncogene homolog
Lin28A/B protein lin-28 homolog A/B
miR/miRNA microRNA
mRISC miRNA-induced silencing complex
mRNA messenger RNA
MS mass spectrometry
MSI Musashi RNA binding protein
MST MicroScale Thermophoresis
HRP horseradish peroxidase
MUFA monounsaturated fatty acid
MYC MYC proto-oncogene
NCI National Cancer Institute
NMR nuclear magnetic resonance
nt nucleotides
OA oleic acid
PCSK9 proprotein convertase subtilisin/kexin type 9
PD Parkinson’s disease
PKC protein kinase C
PK4C9 homocarbonyltopsentin
PLK polo-like kinase
pre-miR precursor microRNA
pre-mRNA precursor messenger RNA
pri-miR primary microRNA
qRT-PCR quantitative reverse transcription-polymerase chain reaction
RBP RNA-binding protein
RNA ribonucleic acid
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RNAi RNA interference
RRM RNA recognition motif
RSV respiratory syncytial virus
SAR Structure-activity relationship
siRNA small interfering RNA
SMA spinal muscular atrophy
SMN survival motor neuron
snRNP small nuclear ribonucleoproteins
SOX2 sex-determining region y-box2
SPR surface plasma resonance
SR proteins serine-arginine-rich proteins
SRSF2 serine/arginine rich splicing factor 2
ss splicing site
SYNCRIP synaptotagmin binding cytoplasmic RNA interacting protein
TNF-α tumour necrosis factor-α
Trim25 tripartite motif-containing 25
TSL2 terminal stem-loop 2
TTR transthyretin
TUT4 terminal uridylyltransferase 4
UTR untranslated region
VEGFR vascular endothelial growth factor receptor
XIAP X-linked inhibitor of apoptosis protein
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